Aims Dyspnoea often occurs in patients with acute coronary syndrome (ACS) treated with
ticagrelor compared with other anti-platelet agents and is a cause of drug discontinuation …

The occurrence of dyspnoea in acute coronary syndrome (ACS) patients has always been
considered a challenging diagnostic and therapeutic clinical scenario. P2Y12 platelet …

Ticagrelor is more effective than clopidogrel in the prevention of myocardial infarction and
death after acute coronary syndrome (ACS)[1]. However, dyspnea is a relatively frequent …

Dyspnoea, a common and multifactorial symptom in patients with acute coronary syndrome,
has been associated with lower quality of life and hospital readmission. Prescriber …

Ticagrelor, a P2Y12 receptor antagonist, is used in combination with aspirin in patients with
coronary artery disease. Recent reports suggest that ticagrelor might induce central sleep …

(1) Background: The aim of this study was to determine clinical and genetic factors
predicting the development of dyspnea in patients receiving ticagrelor.(2) Methods: A total of …

Ticagrelor, a recently approved platelet antagonist indicated for the reduction of thrombotic
cardiovascular events in patients with acute coronary syndrome (ACS), has been reported to …

Aims To describe the incidence of dyspnoea and its associations with demographic
characteristics and clinical outcomes in patients with acute coronary syndromes (ACS) …

Objectives: We prospectively assessed cardiac and pulmonary function in patients with
stable coronary artery disease (CAD) treated with ticagrelor, clopidogrel, or placebo in the …

We read with great interest the paper 'Effect of ticagrelor-related dyspnea on compliance
with therapy in acute coronary syndrome patients' by Gaubert et al.[1], a multicenter …